Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed malignancy, meeting 1 of the following criteria:

- Solid tumor that is refractory to ≥ 1 line of standard treatment OR for which no
standard therapy is available

- Must have ≥ 1 lesion amenable to percutaneous biopsy (for solid tumor
patients enrolled after the initial phase of the study)

- Chronic lymphocytic leukemia (CLL) or follicular lymphoma with no current
indication for standard therapy OR disease that has failed ≥ 1 line of standard
therapy

- No disease-associated symptoms requiring immediate therapy or other interventions

- Must be willing to undergo tumor biopsies* after the initial phase of the study NOTE:
*Patients with CLL undergo peripheral blood collection instead of biopsy

- No primary brain tumors, brain metastases, or leptomeningeal disease

PATIENT CHARACTERISTICS:

- ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

- Life expectancy ≥ 3 months

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 9 g/dL

- Bilirubin < 1.5 times upper limit of normal (ULN)

- AST and ALT ≤ 2.5 times ULN

- Creatinine < 1.5 times ULN OR creatinine clearance ≥ 60 mL/min

- INR ≤ 1.4

- PTT ≤ 36 seconds

- Calcium (corrected) normal

- Magnesium < 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 30 days after study
completion

- No history of seizures

- No evidence of bleeding diathesis

- No uncontrolled intercurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmias

- No psychiatric illness or social situations that would limit study compliance

PRIOR CONCURRENT THERAPY:

- At least 2 weeks since prior radiation therapy or surgery and recovered

- At least 2 weeks since other prior therapy and recovered

- No concurrent antiretroviral therapy for HIV-positive patients

- No concurrent lung, liver, or mediastinal lymph node biopsies

- No other concurrent investigational agents